Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,644 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma.
Amioka K, Kawaoka T, Kinami T, Yamasaki S, Kosaka M, Johira Y, Yano S, Naruto K, Ando Y, Fujii Y, Uchikawa S, Ono A, Yamauchi M, Imamura M, Kosaka Y, Ohya K, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Morio K, Moriya T, Naeshiro N, Nonaka M, Aisaka Y, Azakami T, Hiramatsu A, Aikata H, Oka S. Amioka K, et al. Among authors: oka s. Cancers (Basel). 2022 Oct 16;14(20):5066. doi: 10.3390/cancers14205066. Cancers (Basel). 2022. PMID: 36291850 Free PMC article.
Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices.
Shirane Y, Murakami E, Imamura M, Kosaka M, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Ando Y, Uchikawa S, Teraoka Y, Uchida T, Fujino H, Ono A, Nakahara T, Kawaoka T, Miki D, Yamauchi M, Okamoto W, Tsuge M, Chosa K, Awai K, Aikata H, Oka S. Shirane Y, et al. Among authors: oka s. BMC Gastroenterol. 2022 Dec 22;22(1):535. doi: 10.1186/s12876-022-02616-z. BMC Gastroenterol. 2022. PMID: 36550416 Free PMC article.
Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma-Consideration of the Locations of Target Lesions.
Yano S, Kimura T, Kawaoka T, Kinami T, Yamasaki S, Johira Y, Kosaka M, Amioka K, Naruto K, Ando Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Hirokawa J, Nagata Y, Aikata H, Oka S. Yano S, et al. Among authors: oka s. Cancers (Basel). 2023 Jan 30;15(3):846. doi: 10.3390/cancers15030846. Cancers (Basel). 2023. PMID: 36765804 Free PMC article.
Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein.
Kinami T, Amioka K, Kawaoka T, Uchikawa S, Yamasaki S, Kosaka M, Johira Y, Yano S, Naruto K, Ando Y, Yamaoka K, Fujii Y, Fujino H, Nakahara T, Ono A, Murakami E, Okamoto W, Yamauchi M, Miki D, Tsuge M, Imamura M, Aikata H, Oka S. Kinami T, et al. Among authors: oka s. Cancers (Basel). 2023 Apr 14;15(8):2304. doi: 10.3390/cancers15082304. Cancers (Basel). 2023. PMID: 37190231 Free PMC article.
Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
Johira Y, Nakahara T, Kinami T, Yamasaki S, Kosaka M, Shirane Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Ando Y, Kosaka Y, Kodama K, Uchikawa S, Fujino H, Ono A, Murakami E, Okamoto W, Yamauchi M, Kawaoka T, Hayes CN, Tsuge M, Imamura M, Aikata H, Oka S. Johira Y, et al. Among authors: oka s. BMC Gastroenterol. 2023 Jun 28;23(1):222. doi: 10.1186/s12876-023-02851-y. BMC Gastroenterol. 2023. PMID: 37380950 Free PMC article.
Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes.
Ogawa Y, Nakahara T, Ando Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Ono A, Murakami E, Kawaoka T, Miki D, Yamauchi M, Tsuge M, Imamura M, Oka S. Ogawa Y, et al. Among authors: oka s. Eur J Gastroenterol Hepatol. 2023 Sep 1;35(9):989-996. doi: 10.1097/MEG.0000000000002588. Epub 2023 Jun 6. Eur J Gastroenterol Hepatol. 2023. PMID: 37395206
The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.
Chihiro K, Kawaoka T, Uchikawa S, Kinami T, Yamasaki S, Kosaka M, Johira Y, Yano S, Amioka K, Naruto K, Ando Y, Yamaoka K, Teraoka Y, Uchida T, Fujino H, Nakahara T, Ono A, Murakami E, Okamoto W, Yamauchi M, Miki D, Tsuge M, Imamura M, Aikata H, Oka S. Chihiro K, et al. Among authors: oka s. Oncology. 2023;101(8):491-501. doi: 10.1159/000530991. Epub 2023 Jul 10. Oncology. 2023. PMID: 37429266
Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Kikugawa C, Uchikawa S, Kawaoka T, Kinami T, Yano S, Amioka K, Naruto K, Ando Y, Yamaoka K, Tsuge M, Kosaka Y, Ohya K, Mori N, Takaki S, Tsuji K, Kouno H, Kohno H, Morio K, Moriya T, Nonaka M, Aisaka Y, Masaki K, Honda Y, Naeshiro N, Hiramatsu A, Aikata H, Oka S. Kikugawa C, et al. Among authors: oka s. Oncology. 2024;102(3):239-251. doi: 10.1159/000533859. Epub 2023 Sep 20. Oncology. 2024. PMID: 37729889
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Yano S, Kawaoka T, Yamasaki S, Johira Y, Kosaka M, Shirane Y, Miura R, Amioka K, Naruto K, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Miki D, Tsuge M, Teraoka Y, Kouno H, Takaki S, Mori N, Tsuji K, Oka S. Yano S, et al. Among authors: oka s. Cancers (Basel). 2023 Nov 14;15(22):5406. doi: 10.3390/cancers15225406. Cancers (Basel). 2023. PMID: 38001666 Free PMC article.
2,644 results